CI Global Health Sciences Corporate Class

Series A USD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date July 1996
CAD Total net assets ($CAD)
As at 2026-02-27
$147.1 million
NAVPS
As at 2026-03-10
$37.0740
MER (%)
As at 2025-09-30
2.34
Management fee (%) 1.90
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.7240

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

A ISC 301
DSC SO* 401
LL SO 1401
F 324
P 90324
*No new purchases directly into switch only funds.

Performance2 As at 2026-02-28

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
0.10% 0.28% -0.31% 12.94% 1.82% 3.50% -0.45% 3.36% 7.29%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.7240
2021-03-26 0.2492
2020-12-18 0.3973
2020-09-25 0.3778
2020-06-26 0.2765
Payable date Total
2020-03-20 0.6464
2019-12-13 0.4049
2019-09-27 0.4529
2019-06-21 0.4275
2019-03-22 0.6736

Management team

First we'll display the Team Company and then the Team members
Greg Quickmire
Peter Hofstra

CI Global Health Sciences Corporate Class

Series A USD
 
Portfolio allocations4 As at 2026-02-28
Asset allocation (%)
  • US Equity 78.86
  • International Equity 19.86
  • Cash and Equivalents 1.29
  • Other -0.01
Sector allocation (%)
  • Healthcare 95.45
  • Exchange Traded Fund 3.27
  • Cash and Cash Equivalent 1.29
  • Other -0.01
Geographic allocation(%)
  • United States 79.39
  • United Kingdom 12.32
  • Switzerland 7.58
  • Canada 0.72
  • Other -0.01
Top holdings5
Sector (%)
1. Eli Lilly and Co Drugs 13.54%
2. AstraZeneca PLC Drugs 10.74%
3. Thermo Fisher Scientific Inc Healthcare Equipment 7.60%
4. Boston Scientific Corp Healthcare Equipment 7.54%
5. Johnson & Johnson Drugs 7.25%
6. DexCom Inc Healthcare Equipment 5.95%
7. AbbVie Inc Drugs 5.42%
8. IQVIA Holdings Inc Drugs 5.27%
9. Stryker Corp Healthcare Equipment 5.14%
10. Intuitive Surgical Inc Healthcare Equipment 5.05%
11. Merck & Co Inc Drugs 4.51%
12. Roche Holding AG - Partcptn Drugs 3.96%
13. SPDR S&P Biotech ETF (XBI) Exchange Traded Fund 3.27%
14. Gilead Sciences Inc Drugs 2.81%
15. Vertex Pharmaceuticals Inc Drugs 2.45%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.